Adding perioperative tislelizumab to neoadjuvant chemotherapy and surgery can improve outcomes in patients with NSCLC, a phase 3 trial suggests. Adding perioperative tislelizumab to neoadjuvant chemotherapy and surgery can improve outcomes in patients with NSCLC, a phase 3 trial suggests.